Upcoming Webinars:

Principles of Ensuring Data Integrity

February 28, 2019  09:00 am South African Standard Time (SAST)

Register here!


Featured Webinars:

MembranePlus™ v2 webinar: Stimulate your kinetic understanding…

Use of oral absorption modelling to characterize drug release and absorption of a BCS II compound from IR formulations

Watch Past Webinars

DILIsym® v8A Release Webinar

DILIsym is a mechanistic, predictive software tool focused on predicting and understand drug-induced liver injury across species. DILIsym version 8A is packed with exciting new features.

Stream Download

Molecular Determinants of Cell Permeability Beyond the Rule of 5

Molecules that violate conventional guidelines for druglikeness—such as the Rule-of-5—are of increasing interest as chemical probes and drugs for intractable pharmacological targets.

Stream Download

DDDPlus v6: In Vitro Dissolution… Reimagined

In vitro-in vivo extrapolation (IVIVE) has been a major focus of biopharmaceutics research over the last 20 years, and integration of in silico models built in GastroPlus™ help researchers identify in vitro methods for dissolution and precipitation that are more predictive. DDDPlus™ 6.0 is our updated in vitro platform that provides new functionality and models to evaluate precipitation kinetics of formulations.

Stream Download

Applying GastroPlus Modeling Establish Level A IVIVCs Waive Biostudies

Bioavailability/bioequivalence (BA/BE) evaluation by employing in vitro dissolution/release data and clinically relevant specification is required by the regulators. For BCS 1/BCS 3 drugs formulated as immediate release (IR) oral dosage forms, a BCS-based biowaiver may be granted based on the in vitro dissolution profiles generated across the physiologically relevant pH range. For drugs/formulations with dissolution/release limited/controlled absorption, establishing Level A in vitro – in vivo correlations (IVIVCs) can be applied and further utilized to assess whether BA/BE is recommended.

Stream Download

Applying MAM/PBPK Modeling to Predict Positive/Negative Food Effects: Approaches and Special Considerations

It is widely recognized that food can affect the absorption of orally administered drugs. In the course of pharmaceutical development, food is evaluated clinically as part of the early single or multiple ascending dose studies; additional evaluations often take place when there are formulation changes. The outcome of these studies informs dosing instructions both during the conduct of clinical trials as well as on the product label.

Stream Download

The India GastroPlus™ User Group Webinar: Using In Silico Inputs to Inform GastroPlus Models

Significant enhancements have been made to the HTPK Simulation, MedChem Studio™, and ADMET Modeler™ modules in ADMET Predictor 9.

Stream Download

ADMET Predictor 9™ Release Webinar: Streamline Your Drug Design with ADMET Predictor 9!

We are pleased to announce the release of ADMET Predictor™ 9! Significant enhancements have been made to the HTPK Simulation, MedChem Studio™, and ADMET Modeler™ modules.

Stream Download

GastroPlus™ 9.6 Release Webinar: Improvements Supporting R&D Through Regulatory Interactions

We are pleased to announce the release of GastroPlus™ 9.6! These improvements in our top-ranked PBPK modeling platform support discovery/preclinical/clinical R&D work through regulatory interactions.

Stream Download

Discovery PBPK: How to enhance the expected accuracy of bioavailability predictions for NCEs that are not primarily metabolized

In this webinar, we will review the accuracy of purely in silico estimates of bioavailability and the chemistry classification of new chemical entity (NCE) molecules that are easier or harder to...

Stream Download

What’s new in PKPlus™ version 2?

In this webinar, we will demonstrate how PKPlus 2 combines functionality and flexibility for all PK analyses, providing the capabilities to meet the needs of scientists across departments at...

Stream Download